6/8/2022 8:03:42 AM
Vertex's Inaxaplin Granted Breakthrough Therapy Designation By
FDA And Priority Medicines Designation By EMA
6/2/2022 10:21:57 AM
Vertex And CRISPR Announce Acceptance Of Late-Breaking Abstract For CTX001 At 2022 Annual EHA Congress
5/31/2022 8:07:48 AM
Vertex To Present New Data On VX-880 Clinical Trial
5/5/2022 4:26:21 PM
Vertex Pharma Q1 EPS $2.96 Vs. $2.49 Year Ago
5/2/2022 8:34:56 AM
Vertex Updates On Phase 1/2 Clinical Trial Of VX-880 For Treatment Of Type 1 Diabetes
3/25/2022 8:02:49 AM
Vertex :Canada Grants Marketing Authorization For KALYDECO For Patients With Cystic Fibrosis Ages Of 4 Months -18 Yrs
3/22/2022 8:07:18 AM
Vertex Advances VX-147 Into Pivotal Clinical Development For People With APOL1-Mediated Kidney Disease
1/26/2022 4:55:40 PM
Vertex Pharma Q4 EPS $3.00 Vs. $2.30 Last Year
1/11/2022 3:06:38 AM
Vertex Pharma: EU Approves KAFTRIO In Combination With Ivacaftor For Cystic Fibrosis In Patients Ages 6 Through 11 Years